Beneficial Effects of Human Papillomavirus Vaccine for Prevention of Cervical Abnormalities in Miyagi, Japan

Nobuyoshi Ozawa,1 Kiyoshi Ito,2 Toru Tase,3 Hirohito Metoki4 and Nobuo Yaegashi5

1Ozawa Women’s General Clinic, Sendai, Miyagi, Japan
2Disaster Obstetrics and Gynecology, International Research Institute of Disaster Science, Tohoku University, Sendai, Miyagi, Japan
3Department of Gynecology, Miyagi Cancer Center, Natori, Miyagi, Japan
4Division of Public Health, Hygiene and Epidemiology, Tohoku Medical and Pharmaceutical University Faculty of Medicine, Sendai, Miyagi, Japan
5Department of Obstetrics and Gynecology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan

Prevention of cervical cancer has been unsuccessful in Japan because of low rates of cancer screening and vaccination. The Vaccine Adverse Review Committee of the Japanese Government investigated 2,475 adverse events and reported 617 (6.9/100,000) severe cases and 176 (2.0/100,000) cases with chronic pain. The proactive recommendation for human papillomavirus (HPV) vaccination has been suspended since June 2013. In this study, we examined vaccination rate and incidence of abnormal cervical cytology in women aged 20 to 24 years attending cancer screening in Miyagi. Among the 3,272 women who underwent a health check in the fiscal year 2014 (April 2014-March 2015), 332 (10.2%) received a HPV vaccination. The HPV vaccination rates were 42.3%, 10%, 17.5%, 3.8% and 4.0% in women aged 20, 21, 22, 23 and 24 years, respectively. The rates of atypical squamous cells of undetermined significance (ASC-US) or worse were 2.41% (8/332) in women with HPV vaccination and 5.03% (148/2,940) in those without HPV vaccination, indicating a significant decrease in vaccinated women (p = 0.03). ASC-US cases were referred to HPV DNA tests. In addition, the rates of high grade squamous intraepithelial lesion (HSIL) or worse were 0.30% (1/332) in women with HPV vaccination and 0.82% (24/2,940) in those without HPV vaccination, showing the marginal decrease in women who were vaccinated (p = 0.3). Thus, this study indicates that HPV vaccination is associated with a reduction in the incidence of cervical abnormalities, suggesting a need for scientific discussion of reinstatement of proactive recommendation for HPV vaccine in Japan.

Keywords: ASC-US; cervix; cytology; HPV vaccine; uterine cervical cancer screening

In July 2016, a representative of an organization of people affected by HPV vaccine reported that sixty-three girls had filed lawsuits against the Japanese Government and two vaccine companies. To date, the Japanese Government has not reinstated a proactive recommendation for use of HPV vaccine. The risks of the vaccine are easily understood, whereas the merits of the vaccine are not easily understood. Therefore, we examined the short-term effects of HPV vaccine in Japan by investigating vaccination rates and the incidence of abnormal cytology.

**Subjects and Methods**

The subjects were women aged 20 to 24 years who underwent uterine cervical cancer screening in Miyagi Prefecture in the fiscal year (FY) 2014 (April 2014-March 2015). We asked each subject to report her history of vaccination in a questionnaire. Cervical cytology and history of vaccination were also examined using data of the Miyagi Cancer Society. Statistical analysis was performed using the $\chi^2$ test.

The present study and the questionnaire were discussed by the Gynecological Exam Committee of Miyagi Cancer Society and were approved by individual municipal governments. This study was approved by the ethics committee of Miyagi Cancer Society (approved number 1508).

**Results**

Among the 3,272 women aged 20-24 years who underwent a health check in FY2014, 332 (10.2%) had received an HPV vaccination (Table 1). The rates of vaccination were 42.3%, 10.0%, 17.5%, 3.8%, and 4.0% in those aged 20, 21, 22, 23, and 24 years, respectively (Table 1).

The effect of HPV vaccination was evaluated, based on the Bethesda System for cervical cytology (Fig. 1). The overall results of cervical cytology are summarized in Table 2. Cases of atypical squamous cells of undetermined significance (ASC-US) or worse include all categories, except for negative for intraepithelial lesion or malignancy (NILM). ASC-US cases were subjected to HPV DNA tests and further colposcopic examinations, whereas there was no need to do further examinations for cases of NILM. The rates of ASC-US or worse were 2.41% (8/332) in women with HPV vaccination and 5.03% (148/2,940) in cases without HPV vaccination (Table 3). These results indicate that vaccination resulted in a significant decrease in the rate of ASC-US or worse ($p = 0.03$). The extent of the reduction was 52.1%.

Table 4 summarizes the cases of high grade squamous intraepithelial lesion (HSIL) or worse and cases of low grade squamous intraepithelial lesion (LSIL) or better. Cases of HSIL or worse include HSIL, squamous cell carcinoma (SCC), atypical glandular cells (AGC), adenocarcinoma in situ (AIS), adenocarcinoma, and other malignancy, while cases of LSIL or better include all categories, except for HSIL, SCC, AGC, AIS, adenocarcinoma and other malignancy (see Fig. 1). The cases of HSIL or worse were likely to be treated after colposcope. In contrast, most cases of LSIL or better were not necessarily treated. The rates of HSIL or worse were 0.30% (1/332) in vaccinated women and 0.82% (24/2,940) in those without HPV vaccination (Table 5). The rate of HSIL or worse was lower in vaccinated subjects, although the degree of the decline was not statistically significant ($p = 0.3$). The extent of the reduction was 63.4%.

**Discussion**

The vaccination rate of women aged 20 years who underwent uterine cervical cancer screening was 42.3% in FY2014. It is likely that women who undergo vaccination will receive uterine cervical cancer screening in the coming years. In addition, the beneficial effects of vaccination may become more apparent over time. In this study, we compared the results of cervical cytology in women aged 20 to 24 years with and those without vaccination. The rate of ASC-US or worse was significantly lower and the rate of HSIL or worse tended to be lower in women who had undergone HPV vaccination.

Several clinical trials have shown the effects of quadrivalent HPV vaccine (Villa et al. 2007) and bivalent HPV vaccine (Paavonen et al. 2009). In Australia, Crowe et al. (2014) showed a 43% decrease in the rate of atypical cells and a 62% decrease of HSIL in women aged 22-25 years.

<table>
<thead>
<tr>
<th>Age Group</th>
<th>20 y.o.</th>
<th>21 y.o.</th>
<th>22 y.o.</th>
<th>23 y.o.</th>
<th>24 y.o.</th>
<th>Total Cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>HPV vaccination (+)</td>
<td>112</td>
<td>78</td>
<td>75</td>
<td>29</td>
<td>38</td>
<td>332</td>
</tr>
<tr>
<td>HPV vaccination (-)</td>
<td>153</td>
<td>720</td>
<td>428</td>
<td>728</td>
<td>911</td>
<td>2,940</td>
</tr>
<tr>
<td>Total cases</td>
<td>265</td>
<td>798</td>
<td>503</td>
<td>757</td>
<td>949</td>
<td>3,272</td>
</tr>
<tr>
<td>Rate</td>
<td>42.3%</td>
<td>10.0%</td>
<td>17.5%</td>
<td>3.8%</td>
<td>4.0%</td>
<td>10.2%</td>
</tr>
</tbody>
</table>
with three vaccinations (after a lapse of 7 years). A report in Denmark (Baldur-Felskov et al. 2014) on uterine cervical cancer screening for women aged 20-21 years showed that the rates of atypical cells, cervical intraepithelial neoplasia (CIN) 2 and CIN3 decreased by about 60%, 73% and 80%, respectively. Likewise, in Scotland, Pollock et al. (2014) showed that the rate of CIN3 decreased by about 55% after vaccination.

The subjects in Miyagi Prefecture in Japan were examined only a few years after the start of HPV vaccination. We thus found that the rate of ASC-US or worse was significantly lower in vaccinated women and the rate of HSIL or worse was marginally lower in those who were vaccinated. These data are consistent with the findings in Australia, Denmark and Scotland. However, in Japan, due to the potential adverse effects, such as chronic pain, the recommendation for HPV vaccination has been suspended since 2013.

Only five years have passed since commencement of
HPV vaccination in Japan. The incidence of abnormal cytology found in uterine cervical cancer screening showed a noticeable difference between women with and those without a history of HPV vaccination. HPV vaccination is associated with a significant reduction in the incidence of ASC-US or worse. Therefore, further follow-up studies of HPV vaccination and cervical abnormalities are required in Japan. There is also a need to establish a system for treatment of patients with adverse events after injection of HPV vaccine.

**Acknowledgments**

We would like to express our deep gratitude to Mr. Masaaki Otomo, the staff members of the Miyagi Cancer Society, and physicians of the Gynecological Exam Committee for their assistance with data collection and analysis.

**Conflict of Interest**

The authors declare no conflict of interest.

**References**


Villa, L.L., Kjaer, K., Paavonen, J., Lehtinen, M., Muñoz, N.,